Print Preview Area

GlaxoSmithKline provides further update on divestment of non-core over-the-counter (OTC) brands
GlaxoSmithKline, 03/16/2012

GSK announced its intention to divest non–core Consumer Healthcare OTC products predominantly in the United States and Europe with aggregate sales of approximately £500 million. The proposed divestment is designed to realise value for shareholders and simplify GSK's Consumer Healthcare business by enabling it to focus on priority brands and markets.

Get reports via email to claim your reading activity at MDLinx as Category 2 CME (It takes less than a minute)

Stay current on the latest literature, research and clinical news
Get special communications and offers from MDLinx and our sponsors
Receive invitations to paid market research

View Samples and Register

Stay current - Media Tool

Newsletter

RSS

Facebook

Receive free subspecialty
"5-minute updates" via email

Send the E-mail Newsletter to a Colleague

♦ Subscribe to our free RSS feeds:
Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More ♦

♦ Follow Us on Twitter
Twitter is a rich source of instantly updated information. Join today and follow @MDLinx to start receiving tweets. Learn More ♦

♦ Follow Us on Facebook

Search the latest
Pharma News Jobs
@MDLinx Career Center
View the full listing of physician jobs

Enter your email address and your password will be sent to you.
Email:

E-mail:
Password:
	Remember me Forgot your password?

GlaxoSmithKline provides further update on divestment of non-core over-the-counter (OTC) brands GlaxoSmithKline, 03/16/2012

GlaxoSmithKline provides further update on divestment of non-core over-the-counter (OTC) brands
GlaxoSmithKline, 03/16/2012